<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01753167</url>
  </required_header>
  <id_info>
    <org_study_id>GV28418</org_study_id>
    <secondary_id>2012-002245-37</secondary_id>
    <nct_id>NCT01753167</nct_id>
  </id_info>
  <brief_title>A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients</brief_title>
  <official_title>A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase II, randomized, double-blind, placebo-controlled study designed to assess the
      safety and clinical activity of multiple intravenous doses of MCMV5322A/MCMV3068A in
      cytomegalovirus (CMV)-seronegative recipients of a renal transplant from a CMV-seropositive
      donor, with use of a preemptive approach for prevention of CMV disease. Participants will be
      randomized into two treatment groups: active or placebo control; both arms will be followed
      preemptively. The study has a planned enrollment of approximately 120 participants (60 active
      and 60 placebo).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2012</start_date>
  <completion_date type="Actual">October 15, 2014</completion_date>
  <primary_completion_date type="Actual">October 15, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With CMV Viral Load Greater than or Equal to (&gt;=) 150 Copies per Milliliter (Copies/mL) During the First 12 Weeks After Transplantation</measure>
    <time_frame>Baseline up to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CMV Viral Load &gt;= 150 Copies/mL During the First 24 Weeks After Transplantation</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Detectable CMV Viral Load &gt;=150 Copies/mL</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Load at the First Detection of CMV DNAemia (&gt;=150 Copies/mL), DNAemia is detection of deoxyribonucleic acid (DNA)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Viral Load on or Following First Detection of CMV DNAemia (&gt;=150 Copies/mL)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Require Initiation of Pre-emptive Antiviral Therapy During the First 12 Weeks and 24 Weeks After Transplantation</measure>
    <time_frame>Baseline up to Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Initiation of First use of Preemptive Antiviral Therapy</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of First use of Preemptive Antiviral Therapy Initiated During the First 12 and 24 Weeks After Transplantation</measure>
    <time_frame>Baseline up to Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CMV Syndrome or Tissue-Invasive CMV Disease During the First 24 Weeks After Transplantation</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Change in CMV Serostatus</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCMV5322A Serum Concentrations</measure>
    <time_frame>Up to 24 hours prior to dosing (Day 1) and 1, 4, 24, and 72 hours postdose; predose (0 hours) and 1 hour postdose on Days 8, 29, 57; on Days 43, 58, 64, 71, 78, 85, 113, and 141; at study completion (Day 169)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCMV3068A Serum Concentrations</measure>
    <time_frame>Up to 24 hours prior to dosing (Day 1) and 1, 4, 24, and 72 hours postdose; predose (0 hours) and 1 hour postdose on Days 8, 29, 57; on Days 43, 58, 64, 71, 78, 85, 113, and 141; at study completion (Day 169)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-therapeutic Antibodies (ATAs) to MCMV5322A and MCMV3068A</measure>
    <time_frame>Predose (0 hours) on Days 1, 29, 57; at Days 85, 113, and 141; and at Study Completion (Day 169)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>MCMV5322A/MCMV3068A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a total of four doses of study drug administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57. MCMV5322A/MCMV3068A will be tested in this study at 10 milligrams per kilogram (mg/kg) of each component antibody. Thus, at each dose, 10 mg/kg of MCMV5322A and 10 mg/kg of MCMV3068A will be tested (20 mg/kg total).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a total of four doses of placebo matched with MCMV5322A/MCMV3068A administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCMV3068A</intervention_name>
    <description>Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.</description>
    <arm_group_label>MCMV5322A/MCMV3068A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCMV5322A</intervention_name>
    <description>Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.</description>
    <arm_group_label>MCMV5322A/MCMV3068A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is scheduled to receive a primary or secondary renal allograft from a
             donor

          -  Participant is seronegative for CMV and is receiving an allograft from a
             CMV-seropositive donor

          -  Female participants of child-bearing age must have a negative pregnancy test result on
             Day 1, prior to infusion

          -  For women who are not postmenopausal or surgically sterile (defined as absence of
             ovaries and/or uterus): agreement to remain completely abstinent or use two methods of
             contraception at all times

        Exclusion Criteria:

          -  Participant is suspected of having CMV disease

          -  Participant has received anti-CMV therapy within the 30 days prior to screening
             (exceptions are the use of acyclovir, valacyclovir, or famciclovir for up to 10 days
             duration for treatment of acute herpes simplex or herpes zoster or participants
             receiving acyclovir or valacyclovir at doses to suppress herpes zoster)

          -  Participants who have received intravenous immunoglobulin (IVIG) within 3 months
             before transplantation or with expectation of receiving IVIG at time of
             transplantation or in the 3 months after transplantation

          -  Participants who have received B cell-depleting therapies (including but not limited
             to rituximab) within 3 months before transplantation or with the expectation of
             receiving such therapy at the time of transplantation or in the 3 months after
             transplantation

          -  Participant is receiving a multi-organ transplant (e.g., liver or pancreas in addition
             to kidney)

          -  Active or chronic hepatic or hepatobiliary disease (including known Gilbert's
             syndrome) or elevations in a hepatic transaminase or bilirubin &gt;= 2 times upper limits
             of normal (ULN)

          -  Participant is unlikely or unwilling to be available for follow-up for the full
             24-week duration of the study

          -  Female participants who are pregnant, plan to become pregnant during the study, or who
             are breastfeeding

          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins or human-derived immunoglobulin
             preparations; or any constituent of MCMV5322A/MCMV3068A or placebo

          -  Active treatment for untreated tuberculosis or other infectious conditions that are
             significant in the judgment of the investigator

          -  Infection with hepatitis B, hepatitis C or human immunodeficiency virus

          -  Previous exposure to any investigational agent within 12 weeks or 5 half-lives

          -  Any other acute or chronic condition, metabolic dysfunction, physical examination
             finding, or clinical laboratory finding giving reasonable suspicion of a disease or
             condition that, in the opinion of the Principal Investigator, contraindicates the use
             of an investigational drug or that may affect the interpretation of the results or
             that renders the participant at high risk for treatment complications

          -  History of alcoholism or substance abuse within 6 months before screening

          -  Participant is expected to require treatment or prophylaxis with an antiviral with
             anti-CMV activity during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA; Kidney &amp; Pancreas Transplantation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Inst. of Renal Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of CA San Francisco; Kidney Transplant Service</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center; Dept of Medicine</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Uni Hospital; Division of Transplant Surgery</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hosp Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System; Gastroenterology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2689</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Uni School of Medicine/Barnes Jewish Hospital; Renal</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erie County Medical Center; Dept. of Nephrology</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati / University of Cincinnati College of Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Univ Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clin Univ de Bxl Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pellegrin-CHU de Bordeaux; Service de Neurologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes; Institut de transplantation urologie-néphrologie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Rangueil; Gastro Enterologie Et Nutrition</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu De Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux De Brabois; Nephrologie</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum &quot;Carl Gustav Carus&quot;; Medizinische Klinik III</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen Zentrum f.Innere Medizin Abt.Nephrologie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik III</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundació Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEIC del Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset; Jubileumskliniken</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Huddinge</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset; Transplantation Surgery</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas NHS Foundation Trust, Guys Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2012</study_first_submitted>
  <study_first_submitted_qc>December 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2012</study_first_posted>
  <disposition_first_submitted>March 7, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 7, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 8, 2017</disposition_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

